论文部分内容阅读
美国Upjohn公司投资1.79亿美元以帮助美国Biopure公司开发血液代用品。该公司已同意接受这类血液代用品的全球销售权。Biopure公司正在研制的血液代用品适用于人类和动物,其中人用血液代用品Hemopure正待获准在美国和欧洲进行人体临床试验。Upjohn公司将承担Hemopure制品临床前和临床期的研究费用。此外,该公司还将对Biopure公司的研制工作进行技术和管理监督。研究预测,由于全世界供血不足,Hemopure每年的潜在市场可达1亿单位。
U.S. Upjohn invested US$179 million to help Biopure develop blood substitutes. The company has agreed to accept global sales rights for such blood substitutes. Biopure is developing blood substitutes for humans and animals, and human blood substitute Hemopure is pending approval for human clinical trials in the United States and Europe. Upjohn will be responsible for pre-clinical and clinical research of Hemopure products. In addition, the company will also conduct technical and management oversight of Biopure’s development work. The study predicts that Hemopure’s potential market can reach 100 million units per year due to insufficient blood supply worldwide.